2023 World Conference on Lung Cancer (Posters)-P1.06. Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer through ID1 Downregulation

P1.06. Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer through ID1 Downregulation - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses the potential benefits of combining trametinib, an MEK1/2 inhibitor, with anti-PD-1 immunotherapy for the treatment of lung cancer. The authors found that trametinib inhibits the expression of a protein called ID1, which is involved in the growth of lung adenocarcinoma. They conducted experiments in vitro and in vivo using lung cancer cells and mouse models, and found that trametinib decreased ID1 expression at the protein level, but increased ID1 mRNA levels. However, when trametinib was combined with anti-PD-1 immunotherapy, it resulted in increased PD-L1 expression (a protein that inhibits the immune response) in lung cancer cells. This sensitized the cancer cells to the anti-PD-1 treatment, leading to reduced tumor growth and improved overall survival in mouse models. The authors also observed an increase in anti-tumor effector CD8 T cells and a decrease in regulatory T cells in the immune population, indicating a positive immune response. These results suggest that trametinib may enhance the efficacy of anti-PD-1 immunotherapy in lung cancer by inhibiting ID1 and increasing PD-L1 expression.

Asset Subtitle

Ignacio Gil-Bazo

Meta Tag

Speaker Ignacio Gil-Bazo

Topic Tumor Biology: Preclinical Biology - Tumor Immunity

Keywords

trametinib

MEK1/2 inhibitor

anti-PD-1 immunotherapy

lung cancer

ID1 protein

lung adenocarcinoma

in vitro

in vivo

PD-L1 expression

immune response